Evidence map›Paper›PMID 37285153›Full record

ArticleJAMA network open2023

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.

Armin Rashidi, Fei Gao, David N Fredricks, Steven A Pergam, Marco Mielcarek, Filippo Milano, Brenda M Sandmaier, Stephanie J Lee

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 36 citations in OpenAlex.

  1. Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. JAC-antimicrobial resistance · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Navigating recurrentAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025
    Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Armin RashidiFred Hutchinson Cancer Center, Seattle, Washington.
Fei GaoBiostatistics, Bioinformatics and Epidemiology Program, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
David N FredricksFred Hutchinson Cancer Center, Seattle, Washington.
Steven A PergamFred Hutchinson Cancer Center, Seattle, Washington.
Marco MielcarekFred Hutchinson Cancer Center, Seattle, Washington.
Filippo MilanoFred Hutchinson Cancer Center, Seattle, Washington.
Brenda M SandmaierFred Hutchinson Cancer Center, Seattle, Washington.
Stephanie J LeeFred Hutchinson Cancer Center, Seattle, Washington.
Fred Hutch Cancer Center · US

Funding

The Gut Microbiota and Graft versus Host Disease (GVHD)R01AI134808 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI FREDRICKS, DAVID NEAL · 2018 to 2022
$4.0M
NIAID NIH HHS R01 AI134808
6 · The paper itself

Abstract

Importance: Certain antibiotic exposures have been associated with increased rates of acute graft-vs-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Since antibiotic exposure can both affect and be affected by infections, analyzing time-dependent exposure in the presence of multiple potential confounders, including prior antibiotic exposures, poses specific analytical challenges, necessitating both a large sample size and unique approaches. Objective: To identify antibiotics and antibiotic exposure timeframes associated with subsequent aGVHD. Design, Setting, and Participants: This cohort study assessed allo-HCT at a single center from 2010 to 2021. Participants included all patients aged at least 18 years who underwent their first T-replete allo-HCT, with at least 6 months of follow-up. Data were analyzed from August 1 to December 15, 2022. Exposures: Antibiotics between 7 days before and 30 days after transplant. Main Outcomes and Measures: The primary outcome was grade II to IV aGVHD. The secondary outcome was grade III to IV aGVHD. Data were analyzed using 3 orthogonal methods: conventional Cox proportional hazard regression, marginal structural models, and machine learning. Results: A total of 2023 patients (median [range] age, 55 [18-78] years; 1153 [57%] male) were eligible. Weeks 1 and 2 after HCT were the highest-risk intervals, with multiple antibiotic exposures associated with higher rates of subsequent aGVHD. In particular, exposure to carbapenems during weeks 1 and 2 after allo-HCT was consistently associated with increased risk of aGVHD (minimum hazard ratio [HR] among models, 2.75; 95% CI, 1.77-4.28), as was week 1 after allo-HCT exposure to combinations of penicillins with a β-lactamase inhibitor (minimum HR among models, 6.55; 95% CI, 2.35-18.20). Conclusions and Relevance: In this cohort study of allo-HCT recipients, antibiotic choices and schedules in the early course of transplantation were associated with aGVHD rates. These findings should be considered in antibiotic stewardship programs.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdolescentAdultAgedAnti-Bacterial AgentsCohort StudiesFemaleHumansMaleMiddle AgedTransplantation, HomologousYoung AdultAnti-Bacterial Agents

Identifiers

PMID37285153
PMCPMC10248746
OpenAlexW4379599729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.